Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 5/2019

01-09-2019 | Review

Metabolic reprogramming in osteoclasts

Author: Kyung-Hyun Park-Min

Published in: Seminars in Immunopathology | Issue 5/2019

Login to get access

Abstract

Osteoclasts are bone-resorbing cells that play an essential role in the remodeling of the bone. Defects in osteoclasts thus result in unbalanced bone remodeling, leading to numerous pathological conditions such as osteoporosis, bone metastasis, and inflammatory bone erosion. Metabolism is any process a cell utilizes to meet its energetic demand for biological functions. Along with signaling pathways and osteoclast-specific gene expression programs, osteoclast differentiation activates metabolic programs. The energy generated from metabolic reprogramming in osteoclasts not only supports the phenotypic changes from mononuclear precursor cells to multinuclear osteoclasts, but also facilitates bone resorption, a major function of terminally differentiated, mature osteoclasts. While oxidative phosphorylation is studied as a major metabolic pathway that fulfills the energy demands of osteoclasts, all metabolic pathways are closely interconnected. Therefore, it remains important to understand the various aspects of osteoclast metabolism, including the roles and effects of glycolysis, glutaminolysis, fatty acid synthesis, and fatty acid oxidation. Targeting the pathways associated with metabolic reprogramming has shown beneficial effects on pathological conditions. As a result, it is clear that a deeper understanding of metabolic regulation in osteoclasts will offer broader translational potential for the treatment of human bone disorders.
Literature
1.
Ikeda K, Takeshita S (2016) The role of osteoclast differentiation and function in skeletal homeostasis. J Biochem 159(1):1–8PubMedCrossRef
2.
Nakashima T, Hayashi M, Takayanagi H (2012) New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 23(11):582–590CrossRefPubMed
3.
Boyce BF (2013) Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res 28(4):711–722PubMedCrossRef
4.
Fuller K, Kirstein B, Chambers TJ (2007) Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond) 112(11):567–575CrossRef
5.
Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4(8):638–649CrossRefPubMed
6.
Feldenberg LR, Thevananther S, del Rio M, de Leon M, Devarajan P (1999) Partial ATP depletion induces Fas- and caspase-mediated apoptosis in MDCK cells. Am J Phys 276(6):F837–F846
7.
8.
9.
10.
Ishii KA, Fumoto T, Iwai K, Takeshita S, Ito M, Shimohata N, Aburatani H, Taketani S, Lelliott CJ, Vidal-Puig A, Ikeda K (2009) Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15(3):259–266CrossRefPubMed
11.
Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM, Wan Y (2010) PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11(6):503–516PubMedPubMedCentralCrossRef
12.
13.
Wei W, Schwaid AG, Wang X, Wang X, Chen S, Chu Q, Saghatelian A, Wan Y (2016) Ligand activation of ERRalpha by cholesterol mediates statin and bisphosphonate effects. Cell Metab 23:479–491PubMedPubMedCentralCrossRef
14.
Zeng R, Faccio R, Novack DV (2015) Alternative NF-kappaB regulates RANKL-induced osteoclast differentiation and mitochondrial biogenesis via independent mechanisms. J Bone Miner Res 30(12):2287–2299PubMedCrossRef
15.
Izawa T, Rohatgi N, Fukunaga T, Wang QT, Silva MJ, Gardner MJ, McDaniel ML, Abumrad NA, Semenkovich CF, Teitelbaum SL, Zou W (2015) ASXL2 regulates glucose, Lipid, and Skeletal Homeostasis. Cell Rep 11(10):1625–1637PubMedPubMedCentralCrossRef
16.
Wilson L, Yang Q, Szustakowski JD, Gullicksen PS, Halse R (2007) Pyruvate induces mitochondrial biogenesis by a PGC-1 alpha-independent mechanism. Am J Phys Cell Phys 292(5):C1599–C1605
17.
Drosatos-Tampakaki Z, Drosatos K, Siegelin Y, Gong S, Khan S, Van Dyke T, Goldberg IJ, Schulze PC, Schulze-Spate U (2014) Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it. J Bone Miner Res 29(5):1183–1195PubMedCrossRef
18.
Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM (2002) Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet 31(3):289–294PubMedCrossRef
19.
Miyazaki T, Iwasawa M, Nakashima T, Mori S, Shigemoto K, Nakamura H, Katagiri H, Takayanagi H, Tanaka S (2012) Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. J Biol Chem 287(45):37808–37823PubMedPubMedCentralCrossRef
20.
Bae S, Lee MJ, Mun SH, Giannopoulou EG, Yong-Gonzalez V, Cross JR, Murata K, Giguere V, van der Meulen M, Park-Min KH (2017) MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. J Clin Invest 127(7):2555–2568PubMedPubMedCentralCrossRef
21.
Nishikawa K, Iwamoto Y, Kobayashi Y, Katsuoka F, Kawaguchi S, Tsujita T, Nakamura T, Kato S, Yamamoto M, Takayanagi H, Ishii M (2015) DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nat Med 21(3):281–287PubMedCrossRef
22.
Lemma S, Sboarina M, Porporato PE, Zini N, Sonveaux P, Di Pompo G, Baldini N, Avnet S (2016) Energy metabolism in osteoclast formation and activity. Int J Biochem Cell Biol 79:168–180PubMedCrossRef
23.
Jin Z, Wei W, Yang M, Du Y, Wan Y (2014) Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization. Cell Metab 20(3):483–498PubMedPubMedCentralCrossRef
24.
Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27:441–464PubMedCrossRef
25.
26.
Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, Ikeda K (2013) Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res 28(11):2392–2399PubMedCrossRef
27.
Chen LQ, Cheung LS, Feng L, Tanner W, Frommer WB (2015) Transport of sugars. Annu Rev Biochem 84:865–894PubMedCrossRef
28.
29.
Murata K, Fang C, Terao C, Giannopoulou EG, Lee YJ, Lee MJ, Mun SH, Bae S, Qiao Y, Yuan R, Furu M, Ito H, Ohmura K, Matsuda S, Mimori T, Matsuda F, Park-Min KH, Ivashkiv LB (2017) Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity 47(1):66–79 e5PubMedPubMedCentralCrossRef
30.
Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Miyamoto K, Tando T, Morioka H, Matsumoto M, Chambon P, Johnson RS, Kato S, Toyama Y, Miyamoto T (2013) HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A 110(41):16568–16573PubMedPubMedCentralCrossRef
31.
Knowles HJ, Athanasou NA (2009) Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol 218:256–264PubMedCrossRef
32.
Knowles HJ, Cleton-Jansen A-M, Korsching E, Athanasou NA (2010) Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J 24:4648–4659PubMedPubMedCentral
33.
Morten KJ, Badder L, Knowles HJ (2013) Differential regulation of HIF-mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts. J Pathol 229:755–764PubMedPubMedCentralCrossRef
34.
Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Miyamoto K, Tando T, Morioka H, Matsumoto M, Chambon P, Johnson RS, Kato S, Toyama Y, Miyamoto T (2013) HIF1 α is required for osteoclast activation by estrogen de fi ciency in postmenopausal osteoporosis. Proc Natl Acad Sci 110:16568–16573PubMedCrossRefPubMedCentral
35.
Leger AJ, Altobelli A, Mosquea LM, Belanger AJ, Song A, Cheng SH, Jiang C, Yew NS (2010) Inhibition of osteoclastogenesis by prolyl hydroxylase inhibitor dimethyloxallyl glycine. J Bone Miner Metab 28(5):510–519PubMedCrossRef
36.
Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8(9):705–713PubMedCrossRef
37.
Ahn H, Lee K, Kim JM, Kwon SH, Lee SH, Lee SY, Jeong D (2016) Accelerated lactate dehydrogenase activity potentiates osteoclastogenesis via NFATc1 signaling. PLoS One 11(4):e0153886PubMedPubMedCentralCrossRef
38.
39.
40.
Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA (2003) M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10(10):1165–1177PubMedCrossRef
41.
Tiedemann K, Le Nihouannen D, Fong JE, Hussein O, Barralet JE, Komarova SV (2017) Regulation of osteoclast growth and fusion by mTOR/raptor and mTOR/rictor/Akt. Front Cell Dev Biol 5:54PubMedPubMedCentralCrossRef
42.
43.
Dai Q, Xie F, Han Y, Ma X, Zhou S, Jiang L, Zou W, Wang J (2017) Inactivation of regulatory-associated protein of mTOR (raptor)/mammalian target of rapamycin complex 1 (mTORC1) signaling in osteoclasts increases bone mass by inhibiting osteoclast differentiation in mice. J Biol Chem 292(1):196–204PubMedCrossRef
44.
Wu H, Wu Z, Li P, Cong Q, Chen R, Xu W, Biswas S, Liu H, Xia X, Li S, Hu W, Zhang Z, Habib SL, Zhang L, Zou J, Zhang H, Zhang W, Li B (2017) Bone size and quality regulation: concerted actions of mTOR in mesenchymal stromal cells and osteoclasts. Stem Cell Reports 8(6):1600–1616PubMedPubMedCentralCrossRef
45.
Tintut Y, Morony S, Demer LL (2004) Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol 24(2):e6–e10
46.
Kim SP, Li Z, Zoch ML, Frey JL, Bowman CE, Kushwaha P, Ryan KA, Goh BC, Scafidi S, Pickett JE, Faugere MC, Kershaw EE, Thorek DLJ, Clemens TL, Wolfgang MJ, Riddle RC (2017) Fatty acid oxidation by the osteoblast is required for normal bone acquisition in a sex- and diet-dependent manner. JCI Insight 2(16)
47.
D.M.A. P.K.LUND, and J.C. MATHI, Lipid composition of normal human bone marrow as determined by column chromatography, Journal of Lipid Resesrch 3(1) (1962)
48.
Kasonga AE, Deepak V, Kruger MC, Coetzee M (2015) Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS One 10(4):e0125145PubMedPubMedCentralCrossRef
49.
Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G (2003) Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res 18(7):1206–1216PubMedCrossRef
50.
Mangano KM, Sahni S, Kerstetter JE, Kenny AM, Hannan MT (2013) Polyunsaturated fatty acids and their relation with bone and muscle health in adults. Curr Osteoporos Rep 11(3):203–212PubMedCrossRef
51.
52.
Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, Darby TM, Weitzmann MN, Mulle JG, Gewirtz AT, Jones RM, Pacifici R (2016) Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 126(6):2049–2063PubMedPubMedCentralCrossRef
53.
Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA (2016) Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol 5(4):e73CrossRef
54.
Lucas S, Omata Y, Hofmann J, Bottcher M, Iljazovic A, Sarter K, Albrecht O, Schulz O, Krishnacoumar B, Kronke G, Herrmann M, Mougiakakos D, Strowig T, Schett G, Zaiss MM (2018) Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. Nat Commun 9(1):55PubMedPubMedCentralCrossRef
55.
Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS (2008) Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab 8(6):512–521PubMedPubMedCentralCrossRef
56.
Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946–1949PubMedCrossRef
57.
Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr (2000) Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 25(1):87–90PubMedCrossRef
58.
Sato T, Morita I, Murota S (1998) Involvement of cholesterol in osteoclast-like cell formation via cellular fusion. Bone 23(2):135–140PubMedCrossRef
59.
Okayasu M, Nakayachi M, Hayashida C, Ito J, Kaneda T, Masuhara M, Suda N, Sato T, Hakeda Y (2012) Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion. J Biol Chem 287(23):19229–19241PubMedPubMedCentralCrossRef
60.
Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, Reszka AA (2004) Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ 11(Suppl 1):S108–S118PubMedCrossRef
61.
Ryu J, Kim H, Chang EJ, Kim HJ, Lee Y, Kim HH (2010) Proteomic analysis of osteoclast lipid rafts: the role of the integrity of lipid rafts on V-ATPase activity in osteoclasts. J Bone Miner Metab 28(4):410–417PubMedCrossRef
62.
Wellen KE, Thompson CB (2012) A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 13(4):270–276PubMedCrossRef
Metadata
Title
Metabolic reprogramming in osteoclasts
Author
Kyung-Hyun Park-Min
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 5/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-019-00757-0

Other articles of this Issue 5/2019

Seminars in Immunopathology 5/2019 Go to the issue

Review

γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity

Introduction

Osteoimmunology: entwined regulation of integrated systems

Review

An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis

Review

Omnipresence of inflammasome activities in inflammatory bone diseases

Review

The role of bone cells in immune regulation during the course of infection

Review

Molecular determinants for the polarization of macrophage and osteoclast
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits